As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth

US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials

 
• By David Wallace
  
Waves Beach Horizon Sunset
As Amgen’s current biosimilars portfolio recedes, bigger opportunities are on the horizon in the next wave • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products